Maria Adelaide Caligo

List of Publications by Year
in descending order

158 papers	8,496 citations	53751 45 h-index	54882 84 g-index
166 all docs	166 docs citations	166 times ranked	10882 citing authors

#	Article	IF	Citations
1	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
2	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genetics in Medicine, 2022, 24, 119-129.	1.1	10
3	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
4	Validation and Data-Integration of Yeast-Based Assays for Functional Classification of BRCA1 Missense Variants. International Journal of Molecular Sciences, 2022, 23, 4049.	1.8	3
5	Nutrition, epigenetic markers and growth in preterm infants. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 3963-3968.	0.7	4
6	Disorders of sexual development with XY karyotype and female phenotype: clinical findings and genetic background in a cohort from a single centre. Journal of Endocrinological Investigation, 2021, 44, 145-151.	1.8	11
7	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
8	Disorders/Differences of Sex Development Presenting in the Newborn With 46,XY Karyotype. Frontiers in Pediatrics, 2021, 9, 627281.	0.9	3
9	Longitudinal Lung Volume Changes by Ultrastructure and Genotype in Primary Ciliary Dyskinesia. Annals of the American Thoracic Society, 2021, 18, 963-970.	1.5	12
10	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
11	Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions. International Journal of Molecular Sciences, 2021, 22, 7693.	1.8	6
12	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
13	Whole exome sequencing in familial isolated primary hyperparathyroidism. Journal of Endocrinological Investigation, 2020, 43, 231-245.	1.8	18
14	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
15	Effect of BRCA1 missense variants on gene reversion in DNA double-strand break repair mutants and cell cycle-arrested cells of Saccharomyces cerevisiae. Mutagenesis, 2020, 35, 189-195.	1.0	12
16	PROMs in post-mastectomy care: Patient self-reports (BREAST-Qâ„¢) as a powerful instrument to personalize medical services. European Journal of Surgical Oncology, 2020, 46, 1034-1040.	0.5	15
17	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
18	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265

#	Article	IF	Citations
19	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
20	Lung Function Longitudinal Study by Phenotype and Genotype in Primary Ciliary Dyskinesia. Chest, 2020, 158, 117-120.	0.4	20
21	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
22	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
23	Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing. Breast Cancer Research and Treatment, 2019, 178, 557-564.	1.1	24
24	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
25	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	1.1	102
26	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
27	Blepharophimosis, Ptosis, Epicanthus Inversus Syndrome: New Report with a 197-kb Deletion Upstream of FOXL2 and Review of the Literature. Molecular Syndromology, 2019, 10, 147-153.	0.3	9
28	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
29	Paternity in 5Î±-Reductase-2 Deficiency: Report of Two Brothers with Spontaneous or Assisted Fertility and Literature Review. Sexual Development, 2019, 13, 55-59.	1.1	7
30	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
31	Mouse mammary tumor virus (MMTV) - like exogenous sequences are associated with sporadic but not hereditary human breast carcinoma. Aging, 2019, 11, 7236-7241.	1.4	17
32	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
33	Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. JCO Precision Oncology, 2018, 2, 1-42.	1.5	19
34	Functional Interaction Between BRCA1 and DNA Repair in Yeast May Uncover a Role of RAD50, RAD51, MRE11A, and MSH6 Somatic Variants in Cancer Development. Frontiers in Genetics, 2018, 9, 397.	1.1	18
35	BRCA1 and BRCA2 5â€² noncoding region variants identified in breast cancer patients alter promoter activity and protein binding. Human Mutation, 2018, 39, 2025-2039.	1.1	15
36	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54

#	Article	IF	Citations
37	Next generation sequencing technologies for a successful diagnosis in a cold case of Leigh syndrome. BMC Neurology, 2018, 18, 99.	0.8	12
38	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
39	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
40	Whole-exome analysis of a Liâ€“Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile. Carcinogenesis, 2017, 38, 938-943.	1.3	8
41	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
42	Carcinosarcoma of the Breast: An Aggressive Subtype of Metaplastic Cancer. Report of a Rare Case in a Young BRCA-1 Mutated Woman. Clinical Breast Cancer, 2017, 17, e31-e35.	1.1	12
43	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	242
44	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
45	Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup. Oncotarget, 2017, 8, 79188-79200.	0.8	5
46	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
47	Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients. Genes Chromosomes and Cancer, 2016, 55, 915-924.	1.5	16
48	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
49	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
50	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
51	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
52	Abstract 1859: Bioinformatic and experimental evaluation of regulatory variants in breast cancer susceptibility genes. , 2016, , .		0
53	Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations. International Journal of Molecular Medicine, 2015, 35, 950-956.	1.8	16
54	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26

#	Article	IF	Citations
55	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
56	BRCA1 gene variant p.P142H associated with male breast cancer: a two-generation genealogic study and literature review. Familial Cancer, 2015, 14, 515-519.	0.9	0
57	FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
58	Identification of BRAF 3â€²UTR Isoforms in Melanoma. Journal of Investigative Dermatology, 2015, 135, 1694-1697.	0.3	12
59	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
60	Expression of human poly (ADP-ribose) polymerase 1 in Saccharomyces cerevisiae: Effect on survival, homologous recombination and identification of genes involved in intracellular localization. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 774, 14-24.	0.4	8
61	MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers. European Journal of Medical Genetics, 2015, 58, 531-539.	0.7	18
62	Association of SULT1A1 Arg213His polymorphism with male breast cancer risk: results from a multicenter study in Italy. Breast Cancer Research and Treatment, 2014, 148, 623-628.	1.1	7
63	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
64	Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing. Clinical Chemistry, 2014, 60, 341-352.	1.5	95
65	Identification of two novel BRCA1-partner genes in the DNA double-strand break repair pathway. Breast Cancer Research and Treatment, 2013, 141, 515-522.	1.1	4
66	Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: A retrospective study in a sample of Italian cancer genetics clinics. Breast, 2013, 22, 1130-1135.	0.9	21
67	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
68	Effect of the expression of BRCA2 on spontaneous homologous recombination and DNA damage-induced nuclear foci in Saccharomyces cerevisiae. Mutagenesis, 2013, 28, 187-195.	1.0	19
69	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	1.1	23
70	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
71	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
72	Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R63.	2.2	22

#	Article	IF	Citations
73	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 136, 295-302.	1.1	4
74	Effects on human transcriptome of mutated BRCA1 BRCT domain: A microarray study. BMC Cancer, 2012, 12, 207.	1.1	5
75	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	1.1	11
76	The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 132, 1119-1126.	1.1	8
77	BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: Novel mutations and unclassified variants. Gynecologic Oncology, 2012, 125, 687-692.	0.6	53
78	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
79	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
80	Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Research, 2011, 13, R40.	2.2	23
81	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	2.2	71
82	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361.	2.9	7
83	A recombination-based method to characterize human BRCA1 missense variants. Breast Cancer Research and Treatment, 2011, 125, 265-272.	1.1	6
84	Effect of the overexpression of BRCA2 unclassified missense variants on spontaneous homologous recombination in human cells. Breast Cancer Research and Treatment, 2011, 129, 1001-1009.	1.1	13
85	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	1.8	18
86	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
87	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	1.1	16
88	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	3.2	47
89	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	1.4	32
90	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	3.0	40

#	Article	IF	Citations
91	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	2.6	91
92	PALB2: a novel inactivating mutation in a Italian breast cancer family. Familial Cancer, 2010, 9, 531-536.	0.9	30
93	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
94	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
95	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers. Breast Cancer Research, 2010, 12, R102.	2.2	25
96	Feline immunodeficiency virus vector as a tool for preventative strategies against human breast cancer. Veterinary Immunology and Immunopathology, 2010, 134, 132-137.	0.5	4
97	Multimodal Assessment of Protein Functional Deficiency Supports Pathogenicity of BRCA1 p.V1688del. Cancer Research, 2009, 69, 7030-7037.	0.4	16
98	Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Annals of Oncology, 2009, 20, 874-878.	0.6	21
99	Reply to BRCA2 splice site mutations in an Italian breast/ovarian cancer family. Annals of Oncology, 2009, 20, 1285-1286.	0.6	0
100	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
101	PIK3CA in Breast Carcinoma. Diagnostic Molecular Pathology, 2009, 18, 200-205.	2.1	34
102	A yeast recombination assay to characterize humanBRCA1missense variants of unknown pathological significance. Human Mutation, 2009, 30, 123-133.	1.1	39
103	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Research and Treatment, 2009, 117, 371-379.	1.1	12
104	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	2.9	15
105	Characterisation of gene expression profiles of yeast cells expressing BRCA1 missense variants. European Journal of Cancer, 2009, 45, 2187-2196.	1.3	6
106	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	2.6	257
107	Reconstructing the Genealogy of a BRCA1 Founder Mutation by Phylogenetic Analysis. Annals of Human Genetics, 2008, 72, 310-318.	0.3	22
108	Choroid plexus carcinoma: a new case associated with a novel TP53 germ line mutation. Neuropathology and Applied Neurobiology, 2008, 34, 564-568.	1.8	5

#	Article	IF	Citations
109	A Novel Breast Cancerâ€“Associated BRIP1 (FANCJ/BACH1) Germ-line Mutation Impairs Protein Stability and Function. Clinical Cancer Research, 2008, 14, 4672-4680.	3.2	56
110	Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRIT Study): Interim Results. Radiology, 2007, 242, 698-715.	3.6	324
111	Usefulness of Technetium-99m Hexamethylpropylene Amine Oxime-Labeled Leukocyte Scintigraphy to Detect Pancreatic Necrosis in Patients with Acute Pancreatitis. Pancreatology, 2007, 7, 459-469.	0.5	46
112	High level of messenger RNA forBRMS1 in primary breast carcinomas is associated with poor prognosis. International Journal of Cancer, 2007, 120, 1169-1178.	2.3	35
113	Identification of novel alternatively splicedBRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues. Genes Chromosomes and Cancer, 2007, 46, 791-795.	1.5	19
114	Association between the BRCA2N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy. BMC Cancer, 2007, 7, 170.	1.1	28
115	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers. Breast Cancer Research and Treatment, 2007, 103, 29-36.	1.1	27
116	RNA-based analysis of BRCA1 and BRCA2 gene alterations. Cancer Genetics and Cytogenetics, 2006, 170, 93-101.	1.0	46
117	Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. International Journal of Cancer, 2006, 118, 1215-1226.	2.3	63
118	Genetic alterations in hereditary breast cancer. Annals of Oncology, 2004, 15, i7-i13.	0.6	45
119	Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. Journal of Medical Genetics, 2004, 41, 278-285.	1.5	55
120	Haplotype analysis of BRCA1 gene reveals a new gene rearrangement: characterization of a 19.9 KBP deletion. European Journal of Human Genetics, 2004, 12, 775-777.	1.4	17
121	Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. European Journal of Human Genetics, 2004, 12, 899-906.	1.4	55
122	Clinicopathological Significance of GADD45 Gene Alterations in Human Familial Breast Carcinoma. Breast Cancer Research and Treatment, 2004, 87, 197-201.	1.1	7
123	The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Human Mutation, 2004, 24, 100-101.	1.1	39
124	Different Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified Mutation. Breast Cancer Research and Treatment, 2003, 81, 71-79.	1.1	22
125	p53 Inactivation is a Rare Event in Familial Breast Tumors Negative for BRCA1 and BRCA2 Mutations. Breast Cancer Research and Treatment, 2003, 82, 1-9.	1.1	16
126	Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative forBRCA1 andBRCA2 alterations. Genes Chromosomes and Cancer, 2002, 33, 235-242.	1.5	106

#	Article	IF	Citations
127	Mutational Analysis of the NM23.H1 Gene in Human Breast Cancer. Cancer Genetics and Cytogenetics, 2000, 121, 181-185.	1.0	5
128	The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation Present in Geographically Diverse Populations. American Journal of Human Genetics, 2000, 67, 207-212.	2.6	100
129	Cyclin D1 Overexpression in Thyroid Carcinomas: Relation with Clinico-Pathological Parameters, Retinoblastoma Gene Product, and Ki67 Labeling Index. Thyroid, 2000, 10, 741-746.	2.4	50
130	Microsatellite alterations and K-ras, TGFbetaRII, IGFRII and bax mutations in sporadic cancers of the gastrointestinal tract.. Oncology Reports, 2000, 7, 1371-5.	1.2	13
131	Mutation Analysis of BRCA1 and BRCA2 in Italian Hereditary and Sporadic Forms of Breast and Ovarian Cancers: Tumor Genotype-Phenotype Correlation in Breast Cancer BRCA-Mutation Carriers. Disease Markers, 1999, 15, 101-102.	0.6	1
132	Insurance Implications for Individuals with a High Risk of Breast and Ovarian Cancer in Europe. Disease Markers, 1999, 15, 159-165.	0.6	13
133	Genetic Testing for Breast Cancer Predisposition in 1999: Which Molecular Strategy and which Family Criteria?. Disease Markers, 1999, 15, 67-68.	0.6	4
134	Ethical, Social and Economic Issues in Familial Breast Cancer: A Compilation of Views from the E.C. Biomed II Demonstration Project. Disease Markers, 1999, 15, 125-131.	0.6	23
135	Risk Estimation as a Decision-Making Tool for Genetic Analysis of the Breast Cancer Susceptibility Genes. Disease Markers, 1999, 15, 53-65.	0.6	8
136	Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours. British Journal of Cancer, 1999, 80, 11-16.	2.9	60
137	Microsatellite alterations andp53, TGFÎ²RII, IGFIIR andBAX mutations in sporadic non-small-cell lung cancer. , 1998, 78, 606-609.		13
138	Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Journal of Cancer, 1998, 34, 1922-1926.	1.3	105
139	Haplotype and Phenotype Analysis of Nine Recurrent BRCA2 Mutations in 111 Families: Results of an International Study. American Journal of Human Genetics, 1998, 62, 1381-1388.	2.6	150
140	A region on the long arm of chromosome 16 is frequently deleted in metastatic node-negative breast cancer.. International Journal of Oncology, 1998, 13, 177-82.	1.4	5
141	NM23 gene expression in human breast carcinomas: Loss of correlation with cell proliferation in the advanced phase of tumor progression. , 1997, 74, 102-111.		26
142	Down-regulation of thenm23.h1 gene inhibits cell proliferation. , 1997, 73, 297-302.		49
143	Down regulation of NM23.H1, NM23.H2 and c-myc genes during differentiation induced by 1,25 dihydroxyvitamin D3. Leukemia Research, 1996, 20, 161-167.	0.4	36
144	Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5/SV40 hybrid virus. British Journal of Cancer, 1996, 73, 1356-1361.	2.9	14

#	Article	IF	Citations
145	BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. Oncogene, 1996, 13, 1483-8.	2.6	37
146	NM23 gene expression correlates with cell growth rate and S-phase. International Journal of Cancer, 1995, 60, 837-842.	2.3	66
147	A low NM23.H1 gene expression identifying high malignancy human melanomas. Melanoma Research, 1994, 4, 179-184.	0.6	23
148	Accumulation of anchorage independent cells showing amplified genes (CAD) during the in vitro propagation of CHEF18 Chinese hamster cells. Cell Proliferation, 1993, 26, 161-170.	2.4	5
149	NM23.H1 Loss of Heterozygpsity in Human Mammary Carcinomas.. Annals of the New York Academy of Sciences, 1993, 698, 136-142.	1.8	4
150	Genomic PCR-SSCP analysis of the metastasis associated NM23-H1 (NME1) gene: a study on colorectal cancer. Anticancer Research, 1993, 13, 2149-54.	0.5	9
151	Thenm23 gene maps to human chromosome band 17q22 and shows a restriction fragment length polymorphism withbg/II. Genes Chromosomes and Cancer, 1992, 4, 84-88.	1.5	52
152	Decreasing expression of NM23 gene in metastatic murine mammary tumors of viral etiology (MMTV). Anticancer Research, 1992, 12, 969-73.	0.5	15
153	Increased rate of base substitution in a hamster mutator strain obtained during serial selection for gene amplification.. Molecular and Cellular Biology, 1990, 10, 6805-6808.	1.1	8
154	Increased rate of base substitution in a hamster mutator strain obtained during serial selection for gene amplification. Molecular and Cellular Biology, 1990, 10, 6805-6808.	1.1	3
155	Time course of sister chromatid exchanges and gene amplification induced by 1-?-d-arabinofuranosylcytosine in V79-AP4 Chinese hamster cells. Chromosoma, 1988, 96, 306-310.	1.0	7
156	Origin of araC-induced endoreduplicated cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1987, 177, 261-265.	0.4	11
157	Proline and serine affect polarity and development of carrot somatic embryos. Cell Differentiation, 1985, 17, 193-198.	1.3	16
158	Stimulation of carrot somatic embryogenesis by proline and serine. Plant Cell Reports, 1984, 3, 210-214.	2.8	54